These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 16294508)

  • 21. Tamoxifen in breast cancer: not so easy to write off.
    Munshi A; Singh P
    Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating elderly patients with hormone sensitive breast cancer: what do the data show?
    Balducci L
    Cancer Treat Rev; 2009 Feb; 35(1):47-56. PubMed ID: 18840391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal breast cancer agents: implications for the primary care provider.
    Lyon DE; Roux G; Voll S
    J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine therapy for breast cancer: an overview.
    Cheung KL
    Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
    [No Abstract]   [Full Text] [Related]  

  • 29. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 30. [Is our current knowledge sufficient for the up-front use of aromatase inhibitors as adjuvant therapy for breast cancer?].
    Lefebvre-Lacoeuille C; Catala L; Descamps P
    J Gynecol Obstet Biol Reprod (Paris); 2009 Oct; 38(6):453-5. PubMed ID: 19640658
    [No Abstract]   [Full Text] [Related]  

  • 31. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 36. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.